Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02145442
Other study ID # OBEX-IFG-2014
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date June 2014
Est. completion date November 2014

Study information

Verified date May 2018
Source Catalysis SL
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

- Obesity is an important and growing public health worldwide

- Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer

- An extensive body of evidence from efficacy trials has shown that weight loss is achievable, however, a modest weight loss is achieved in a small proportion of patients

- Important adverse events have been reported with the use of antiobesity drugs.

- The use of natural products with potential effects inducing weight loss is an alternative strategy for treating patients with overweight and obesity. However, efficacy and safety should be evaluated in RCT.

- Obex combines different molecules with potential effects inducing weight loss and control on metabolic parameters such as fasting glucose, cholesterol and triglycerides.

- Therefore, the administration of Obex in overweight and obese patients with impaired fasting glucose could be an excellent strategy to induce weight loss and ameliorate the metabolic disturbances related to obesity and overweight.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date November 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- Overweight and Obese subjects with and without IFG

- Ability to provide informed consent

Exclusion Criteria:

- Presence of diabetes mellitus, hepatic, renal or cardiovascular disease

- Other diseases associated with insulin resistance (eg. Acromegalia, endogenous hypercortisolism, etc)

- Sepsis or any other condition that could potentially interfere with treatment

- History of bariatric surgery

- Pregnancy or lactation

- Concomitant disease with reduced life expectancy

- Severe psychiatric conditions

- Anyone with chronic medical conditions requiring regular intake of any prescription medications.

- Used drugs for weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Accomplia [rimonabant], Alli [low-dose orlistat], or other similar over-the-counter weight loss remedies or medications) within 3 months of screening

- Are actively participating in, or have participated in a formal weight loss program within the last 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Obex
Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.

Locations

Country Name City State
Cuba National Institute of Endocrinology Plaza de la Revolución Havana

Sponsors (1)

Lead Sponsor Collaborator
Catalysis SL

Country where clinical trial is conducted

Cuba, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the effect of Obex® on fasting glucose levels The primary outcome is to evaluate the effect of the treatment with Obex® on fasting glucose levels Three months of treatment
Primary To determine the safety of serious supplement-related adverse events Adverse events will be evaluated during the three months of treatment Three months of treatment
Secondary To evaluate the effect of Obex® on fasting insulin levels The insulin levels will be evaluated at baseline and at the end of treatment. Three months of treatment
Secondary • To evaluate the effect of Obex® on insulin sensitivity by homeostasis model assessment-estimated insulin resistance (HOMA-IR), calculated from individual serum measures (fasting insulin x fasting glucose/22.5) The HOMA-IR will be evaluated at baseline and at the end of treatment. Three months of treatment
Secondary To evaluate the effect of Obex® on insulin sensitivity by quantitative insulin sensitivity check index, Bennett and Raynaud insulin sensitivity indexes The Quicki, Bennett and Raynaud insulin sensitivity indexes will be evaluated at baseline and at the end of treatment.
QUICKI = [1/[log I0 + log G0], Bennett index (BEN) = 1/(log I0 x log G0), Raynaud index (RAY) = [40/I0])
Three months of treatment
Secondary • To evaluate the effect of Obex® on ß-cell function by homeostatic model assessment-beta cell (HOMA-ß), calculated from individual serum measures (20 x fasting insulin (µU/mL)/fasting glucose (mmol/L)-3.5) The HOMA-B will be evaluated at baseline and at the end of treatment Three months of treatment
Secondary • To evaluate the effect of Obex® on cholesterol, triglyceride and high density lipoprotein cholesterol levels (HDL-c) The cholesterol, triglyceride and HDL-c levels will be evaluated at baseline and at the end of treatment. Three months of treatment
Secondary To evaluate the effect of Obex® on Glycosylated Hemoglobin (HbA1c) The HbA1c will be evaluated at baseline and at the end of treatment. Three months of treatment
Secondary To evaluate the effect of Obex® on the body weight. The body weight will be measured at baseline and at the end of treatment. Three months of treatment
Secondary • To evaluate the effect of Obex® on Body Mass Index (BMI) and Conicity Index (CI) The BMI and CI will be measured at baseline and at the end of treatment. Three months of treatment
Secondary To evaluate the effect of Obex® on the waist and hip circumferences Waist and Hip circumferences will be measured at baseline and at the end of treatment. Three months of treatment
Secondary To evaluate the effect of Obex® on arterial blood pressures (BP) The arterial BP will be evaluated at baseline and at the end of treatment. Three months of treatment
Secondary • To evaluate the effect of Obex® on hepatic enzymes (Alanine aminotransferase, Aspartate aminotransferase, gamma-glutamyltransferase, Alkaline Phosphatase) The hepatic enzymes will be evaluated at baseline and at the end of treatment. Three months of treatment
Secondary To evaluate the effect of Obex® on creatinine and uric acid concentrations The creatinine and uric acid levels will be evaluated at baseline and at the end of treatment. Three months of treatment
Secondary To evaluate the effect of Obex® on haemoglobin and serum iron levels The haemoglobin and iron levels will be evaluated at baseline and at the end of treatment. Three months of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2